Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 46
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Network, transcriptomic and genomic features differentiate genes relevant for drug response

  • Piñero González, Janet, 1977-
  • Gonzalez-Perez, Abel
  • Guney, Emre
  • Aguirre Plans, Joaquim, 1993-
  • Sanz, Ferran
  • Oliva Miguel, Baldomero
  • Furlong, Laura I., 1971-
Understanding the mechanisms underlying drug therapeutic action and toxicity is crucial for the prevention and management of drug adverse reactions, and paves the way for a more efficient and rational drug design. The characterization of drug targets, drug metabolism proteins, and proteins associated to side effects according to their expression patterns, their tolerance to genomic variation and their role in cellular networks, is a necessary step in this direction. In this contribution, we hypothesize that different classes of proteins involved in the therapeutic effect of drugs and in their adverse effects have distinctive transcriptomics, genomics and network features. We explored the properties of these proteins within global and organ-specific interactomes, using multi-scale network features, evaluated their gene expression profiles in different organs and tissues, and assessed their tolerance to loss-of-function variants leveraging data from 60K subjects. We found that drug targets that mediate side effects are more central in cellular networks, more intolerant to loss-of-function variation, and show a wider breadth of tissue expression than targets not mediating side effects. In contrast, drug metabolizing enzymes and transporters are less central in the interactome, more tolerant to deleterious variants, and are more constrained in their tissue expression pattern. Our findings highlight distinctive features of proteins related to drug action, which could be applied to prioritize drugs with fewer probabilities of causing side effects., We received support from ISCIII-FEDER (PI13/00082, CP10/00524, and CPII16/00026), IMI-JU under grant agreements no. 116030 (TransQST) and no. 777365 (eTRANSAFE) resources of which are composed of financial contribution from the EU-FP7 (FP7/2007-2013) and EFPIA companies in kind contribution, and the EU H2020 Program 2014–2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and was supported by grant PT13/0001/0023, of the PE I+D+i 2013-2016, funded by ISCIII and FEDER. The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the MINECO (ref: MDM-2014-0370). AG-P was supported by a Ramón y Cajal contract (RYC-2013-14554). BO and JA-P were supported by MINECO grant BIO2014-57518-R.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

GUILDify v2.0: a tool to identify molecular networks underlying human diseases, their comorbidities and their druggable targets

  • Aguirre Plans, Joaquim, 1993-
  • Piñero González, Janet, 1977-
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
  • Fernández Fuentes, Narcís
  • Oliva Miguel, Baldomero
  • Guney, Emre
The genetic basis of complex diseases involves alterations on multiple genes. Unraveling the interplay between these genetic factors is key to the discovery of new biomarkers and treatments. In 2014, we introduced GUILDify, a web server that searches for genes associated to diseases, finds novel disease genes applying various network-based prioritization algorithms and proposes candidate drugs. Here, we present GUILDify v2.0, a major update and improvement of the original method, where we have included protein interaction data for seven species and 22 human tissues and incorporated the disease-gene associations from DisGeNET. To infer potential disease relationships associated with multi-morbidities, we introduced a novel feature for estimating the genetic and functional overlap of two diseases using the top-ranking genes and the associated enrichment of biological functions and pathways (as defined by GO and Reactome). The analysis of this overlap helps to identify the mechanistic role of genes and protein-protein interactions in comorbidities. Finally, we provided an R package, guildifyR, to facilitate programmatic access to GUILDify v2.0 (http://sbi.upf.edu/guildify2)., The authors received support from the following:ISCIII–FEDER (PI13/00082, CP10/00524, CPII16/00026); IMI-JU under grants agreements no. 116030(TransQST) and no. 777365 (eTRANSAFE), re-sources of which are composed of financial contribu-tion from the EU-FP7 (FP7/2007- 2013) and EFPIAcompanies in kind contribution; the EU H2020Programme 2014–2020 under grant agreementsno. 634143 (MedBioinformatics) and no. 676559(Elixir-Excelerate); the Spanish Ministry of Economy(MINECO) (BIO2017-85329-R, RYC-2015-17519);and“Unidad de Excelencia María de Maeztu,”fundedby the Spanish Ministry of Economy (ref.: MDM-2014-0370). The Research Programme on BiomedicalInformatics is a member of the Spanish NationalBioinformatics Institute, PRB2-ISCIII, and is supportedby Grant PT13/0001/0023 of the PE I+D+i 2013-2016funded by ISCIII and FEDER
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Identifying multiscale translational safety biomarkers using a network-based systems approach

  • Callegaro, Giulia
  • Schimming, Johannes P.
  • Piñero González, Janet, 1977-
  • Kunnen, Steven J.
  • Wijaya, Lukas
  • Trairatphisan, Panuwat
  • van den Berk, Linda
  • Beetsma, Kim
  • Furlong, Laura I.
  • Sutherland, Jeffrey J.
  • Mollon, Jennifer
  • Stevens, James L.
  • van de Water, Bob
Animal testing is the current standard for drug and chemicals safety assessment, but hazards translation to human is uncertain. Human in vitro models can address the species translation but might not replicate in vivo complexity. Herein, we propose a network-based method addressing these translational multiscale problems that derives in vivo liver injury biomarkers applicable to in vitro human early safety screening. We applied weighted correlation network analysis (WGCNA) to a large rat liver transcriptomic dataset to obtain co-regulated gene clusters (modules). We identified modules statistically associated with liver pathologies, including a module enriched for ATF4-regulated genes as associated with the occurrence of hepatocellular single-cell necrosis, and as preserved in human liver in vitro models. Within the module, we identified TRIB3 and MTHFD2 as a novel candidate stress biomarkers, and developed and used BAC-eGFPHepG2 reporters in a compound screening, identifying compounds showing ATF4-dependent stress response and potential early safety signals., This work was supported by the EU-EFPIA Innovative Medicines Initiative 2 (IMI2) Joint Undertaking TransQST project (grant number 116030) and eTRANSAFE project (grant number 777365) (this Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA), the EC Horizon2020 EU-ToxRisk project (grant number 681002), the European Research & Innovation project funded under the European Commission’s Horizon 2020 program RISK-HUNT3R project (grant number 964537) and the Cosmetics Europe/CEFIC Liver Ontology project.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Integrating mechanistic and toxicokinetic information in predictive models of cholestasis

  • Rodríguez-Belenguer, Pablo
  • Mangas Sanjuan, Victor
  • Soria Olivas, Emilio
  • Pastor Maeso, Manuel
Drug development involves the thorough assessment of the candidate's safety and efficacy. In silico toxicology (IST) methods can contribute to the assessment, complementing in vitro and in vivo experimental methods, since they have many advantages in terms of cost and time. Also, they are less demanding concerning the requirements of product and experimental animals. One of these methods, Quantitative Structure-Activity Relationships (QSAR), has been proven successful in predicting simple toxicity end points but has more difficulties in predicting end points involving more complex phenomena. We hypothesize that QSAR models can produce better predictions of these end points by combining multiple QSAR models describing simpler biological phenomena and incorporating pharmacokinetic (PK) information, using quantitative in vitro to in vivo extrapolation (QIVIVE) models. In this study, we applied our methodology to the prediction of cholestasis and compared it with direct QSAR models. Our results show a clear increase in sensitivity. The predictive quality of the models was further assessed to mimic realistic conditions where the query compounds show low similarity with the training series. Again, our methodology shows clear advantages over direct QSAR models in these situations. We conclude that the proposed methodology could improve existing methodologies and could be suitable for being applied to other toxicity end points., The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777365, European Union’s Horizon 2020, and EFPIA. The authors declare that this work reflects only the author’s view and that IMI-JU is not responsible for any use that may be made of the information it contains. Also, this project received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 964537 (RISK-HUNT3R), which is part of the ASPIS cluster.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Guidelines for FAIR sharing of preclinical safety and off-target pharmacology data

  • Briggs, Katharine
  • Bosc, Nicolas
  • Camara, Tima
  • Diaz, Carlos
  • Drew, Phil
  • Drewe, William C.
  • Kors, Jan A.
  • Mulligen, Erik van
  • Pastor Maeso, Manuel
  • Pognan, François
  • Quintana, Jordi
  • Sarntivijai, Sirarat
  • Steger-Hartmann, Thomas
Pre-competitive data sharing can offer the pharmaceutical industry significant benefits in terms of reducing the time and costs involved in getting a new drug to market through more informed testing strategies and knowledge gained by pooling data. If sufficient data is shared and can be co-analyzed, then it can also offer the potential for reduced animal usage and improvements in the in silico prediction of toxicological effects. Data sharing benefits can be further enhanced by applying the FAIR Guiding Principles, reducing time spent curating, transforming and aggregating datasets and allowing more time for data mining and analysis. We hope to facilitate data sharing by other organizations and initiatives by describing lessons learned as part of the Enhancing TRANslational SAFEty Assessment through Integrative Knowledge Management (eTRANSAFE) project, an Innovative Medicines Initiative (IMI) partnership which aims to integrate publicly available data sources with proprietary preclinical and clinical data donated by pharmaceutical organizations. Methods to foster trust and overcome non-technical barriers to data sharing such as legal and IPR (intellectual property rights) are described, including the security requirements that pharmaceutical organizations generally expect to be met. We share the consensus achieved among pharmaceutical partners on decision criteria to be included in internal clearance procedures used to decide if data can be shared. We also report on the consensus achieved on specific data fields to be excluded from sharing for sensitive preclinical safety and pharmacology data that could otherwise not be shared., This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777365 (“eTRANSAFE”). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Uncertainty assessment of proarrhythmia predictions derived from multi-level in silico models

  • Kopańska, Karolina
  • Rodríguez-Belenguer, Pablo
  • Llopis-Lorente, Jordi
  • Trenor, Beatriz
  • Saiz, Javier
  • Pastor Maeso, Manuel
In silico methods can be used for an early assessment of arrhythmogenic properties of drug candidates. However, their use for decision-making is conditioned by the possibility to estimate the predictions' uncertainty. This work describes our efforts to develop uncertainty quantification methods for the predictions produced by multi-level proarrhythmia models. In silico models used in this field usually start with experimental or predicted IC50 values that describe drug-induced ion channel blockade. Using such inputs, an electrophysiological model computes how the ion channel inhibition, exerted by a drug in a certain concentration, translates to an altered shape and duration of the action potential in cardiac cells, which can be represented as arrhythmogenic risk biomarkers such as the APD90. Using this framework, we identify the main sources of aleatory and epistemic uncertainties and propose a method based on probabilistic simulations that replaces single-point estimates predicted using multiple input values, including the IC50s and the electrophysiological parameters, by distributions of values. Two selected variability types associated with these inputs are then propagated through the multi-level model to estimate their impact on the uncertainty levels in the output, expressed by means of intervals. The proposed approach yields single predictions of arrhythmogenic risk biomarkers together with value intervals, providing a more comprehensive and realistic description of drug effects on a human population. The methodology was tested by predicting arrhythmogenic biomarkers on a series of twelve well-characterised marketed drugs, belonging to different arrhythmogenic risk classes., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 777365, supported from European Union’s Horizon 2020 and the EFPIA. Authors declare that this work reflects only the author’s view, and that IMI-JU is not responsible for any use that may be made of the information it contains. Also, this project received funding from the European Union’s Horizon 2020 Research and Innovation programme under Grant Agreement No. 964537 (RISK-HUNT3R), which is part of the ASPIS cluster. We also received funding from the SimCardioTest supported by European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 101016496. J.L.L. is being funded by the Ministerio de Ciencia, Innovacion y Universidades for the “Formacion de Profesorado Universitario” (Grant Reference: FPU18/01659). The work was also partially support by the Dirección General de Política Científica de la Generalitat Valenciana (PROMETEO/2020/043).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Benchmarking post-GWAS analysis tools in major depression: Challenges and implications

  • Pérez-Granado, Judith
  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
Our knowledge of complex disorders has increased in the last years thanks to the identification of genetic variants (GVs) significantly associated with disease phenotypes by genome-wide association studies (GWAS). However, we do not understand yet how these GVs functionally impact disease pathogenesis or their underlying biological mechanisms. Among the multiple post-GWAS methods available, fine-mapping and colocalization approaches are commonly used to identify causal GVs, meaning those with a biological effect on the trait, and their functional effects. Despite the variety of post-GWAS tools available, there is no guideline for method eligibility or validity, even though these methods work under different assumptions when accounting for linkage disequilibrium and integrating molecular annotation data. Moreover, there is no benchmarking of the available tools. In this context, we have applied two different fine-mapping and colocalization methods to the same GWAS on major depression (MD) and expression quantitative trait loci (eQTL) datasets. Our goal is to perform a systematic comparison of the results obtained by the different tools. To that end, we have evaluated their results at different levels: fine-mapped and colocalizing GVs, their target genes and tissue specificity according to gene expression information, as well as the biological processes in which they are involved. Our findings highlight the importance of fine-mapping as a key step for subsequent analysis. Notably, the colocalizing variants, altered genes and targeted tissues differed between methods, even regarding their biological implications. This contribution illustrates an important issue in post-GWAS analysis with relevant consequences on the use of GWAS results for elucidation of disease pathobiology, drug target prioritization and biomarker discovery., IMI2-JU resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA (GA: 116030 TransQST and GA: 777365 eTRANSAFE), and the EU H2020 Programme 2014–2020 (GA: 676559 Elixir-Excelerate); Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya (2017SGR00519), and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII (PT13/0001/0023, of the PE I + D + i 2013–2016)). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO (MDM-2014-0370). JP-G was supported by Instituto de Salud Carlos III-Fondo Social Europeo (FI18/00034). This statement is a requirement from our funding agencies and therefore has to be included in the Funding section.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Making in silico predictive models for toxicology FAIR

  • Cronin, Mark T. D.
  • Belfield, Samuel J.
  • Briggs, Katharine
  • Enoch, Steven J.
  • Firman, James W.
  • Frericks, Markus
  • Garrard, Clare
  • Maccallum, Peter H.
  • Madden, Judith C.
  • Pastor Maeso, Manuel
  • Sanz, Ferran
  • Soininen, Inari
  • Sousoni, Despoina
In silico predictive models for toxicology include quantitative structure-activity relationship (QSAR) and physiologically based kinetic (PBK) approaches to predict physico-chemical and ADME properties, toxicological effects and internal exposure. Such models are used to fill data gaps as part of chemical risk assessment. There is a growing need to ensure in silico predictive models for toxicology are available for use and that they are reproducible. This paper describes how the FAIR (Findable, Accessible, Interoperable, Reusable) principles, developed for data sharing, have been applied to in silico predictive models. In particular, this investigation has focussed on how the FAIR principles could be applied to improved regulatory acceptance of predictions from such models. Eighteen principles have been developed that cover all aspects of FAIR. It is intended that FAIRification of in silico predictive models for toxicology will increase their use and acceptance., This research received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) under grant agreement eTRANSAFE (777365), the European Union’s Horizon 2020 ELIXIR-CONVERGE Project (871075) and research and innovation programme under grant agreement No 964537 (RISK-HUNT3R).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

PretoxTM: a text mining system for extracting treatment-related findings from preclinical toxicology reports

  • Corvi, Javier
  • Ronzano, Francesco
  • Centeno, Emilio
  • Capella Gutiérrez, Salvador Jesús, 1985-
Over the last few decades the pharmaceutical industry has generated a vast corpus of knowledge on the safety and efficacy of drugs. Much of this information is contained in toxicology reports, which summarise the results of animal studies designed to analyse the effects of the tested compound, including unintended pharmacological and toxic effects, known as treatment-related findings. Despite the potential of this knowledge, the fact that most of this relevant information is only available as unstructured text with variable degrees of digitisation has hampered its systematic access, use and exploitation. Text mining technologies have the ability to automatically extract, analyse and aggregate such information, providing valuable new insights into the drug discovery and development process. In the context of the eTRANSAFE project, we present PretoxTM (Preclinical Toxicology Text Mining), the first system specifically designed to detect, extract, organise and visualise treatment-related findings from toxicology reports. The PretoxTM tool comprises three main components: PretoxTM Corpus, PretoxTM Pipeline and PretoxTM Web App. The PretoxTM Corpus is a gold standard corpus of preclinical treatment-related findings annotated by toxicology experts. This corpus was used to develop, train and validate the PretoxTM Pipeline, which extracts treatment-related findings from preclinical study reports. The extracted information is then presented for expert visualisation and validation in the PretoxTM Web App. Scientific Contribution While text mining solutions have been widely used in the clinical domain to identify adverse drug reactions from various sources, no similar systems exist for identifying adverse events in animal models during preclinical testing. PretoxTM fills this gap by efficiently extracting treatment-related findings from preclinical toxicology reports. This provides a valuable resource for toxicology research, enhancing the efficiency of safety evaluations, saving time, and leading to more effective decision-making in the drug development process., JC was partly supported by eTRANSAFE (received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777365 and support from the European Union's Horizon 2020 research and innovation programme and EFPIA).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Genomic and proteomic biomarker landscape in clinical trials

  • Piñero González, Janet, 1977-
  • Rodriguez Fraga, Pablo S.
  • Valls-Margarit, Jordi
  • Ronzano, Francesco
  • Accuosto, Pablo
  • Lambea Jane, Ricard
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
The use of molecular biomarkers to support disease diagnosis, monitor its progression, and guide drug treatment has gained traction in the last decades. While only a dozen biomarkers have been approved for their exploitation in the clinic by the FDA, many more are evaluated in the context of translational research and clinical trials. Furthermore, the information on which biomarkers are measured, for which purpose, and in relation to which conditions are not readily accessible: biomarkers used in clinical studies available through resources such as ClinicalTrials.gov are described as free text, posing significant challenges in finding, analyzing, and processing them by both humans and machines. We present a text mining strategy to identify proteomic and genomic biomarkers used in clinical trials and classify them according to the methodologies by which they are measured. We find more than 3000 biomarkers used in the context of 2600 diseases. By analyzing this dataset, we uncover patterns of use of biomarkers across therapeutic areas over time, including the biomarker type and their specificity. These data are made available at the Clinical Biomarker App at https://www.disgenet.org/biomarkers/, a new portal that enables the exploration of biomarkers extracted from the clinical studies available at ClinicalTrials.gov and enriched with information from the scientific literature. The App features several metrics that assess the specificity of the biomarkers, facilitating their selection and prioritization. Overall, the Clinical Biomarker App is a valuable and timely resource about clinical biomarkers, to accelerate biomarker discovery, development, and application., This work was partially funded by IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 116030 TransQST and GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA: 871075 Elixir-CONVERGE and GA:964537 RISKHUNT3R, which is part of the ASPIS cluster]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519], and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII [PT13/0001/0023, of the PE I + D + i 2013-2016]). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. This work reflects only the author’s view and that the IMI2-JU is not responsible for any use that may be made of the information it contains. The European Commission is not responsible for any use that may be made of the information it contains.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Generating modeling data from repeat-dose toxicity reports

  • López Massaguer, Oriol, 1972-
  • Pinto Gil, Kevin
  • Sanz, Ferran
  • Amberg, Alexander
  • Anger, Lennart T.
  • Stolte, Manuela
  • Ravagli, Carlo
  • Marc, Philippe
  • Pastor Maeso, Manuel
Over the past decades, pharmaceutical companies have conducted a large number of high-quality in vivo repeat-dose toxicity (RDT) studies for regulatory purposes. As part of the eTOX project, a high number of these studies have been compiled and integrated into a database. This valuable resource can be queried directly, but it can be further exploited to build predictive models. As the studies were originally conducted to investigate the properties of individual compounds, the experimental conditions across the studies are highly heterogeneous. Consequently, the original data required normalization/standardization, filtering, categorization and integration to make possible any data analysis (such as building predictive models). Additionally, the primary objectives of the RDT studies were to identify toxicological findings, most of which do not directly translate to in vivo endpoints. This article describes a method to extract datasets containing comparable toxicological properties for a series of compounds amenable for building predictive models. The proposed strategy starts with the normalization of the terms used within the original reports. Then, comparable datasets are extracted from the database by applying filters based on the experimental conditions. Finally, carefully selected profiles of toxicological findings are mapped to endpoints of interest, generating QSAR-like tables. In this work, we describe in detail the strategy and tools used for carrying out these transformations and illustrate its application in a data sample extracted from the eTOX database. The suitability of the resulting tables for developing hazard-predicting models was investigated by building proof-of-concept models for in vivo liver endpoints., Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115002 (eTOX), resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contributions. Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 777365 (eTRANSAFE). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA companies' in-kind contributions.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches

  • Niarakis, Anna
  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
  • COVID-19 Disease Map Community
Introduction: The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing. Methods: Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue- or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors. Results: Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19. Discussion: The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. AN acknowledges support from SANOFI-AVENTIS R&D via the CIFRE contract, n° 2020/0766. MK, FH, NP, FE, and CE acknowledge the support of the ZonMw COVID-19 programme (Grant No. 10430012010015). JD Spanish Ministry of Science and Innovation (Grant no. PID2020-117979RB-I00) and Instituto de Salud Carlos III (Grant no. IMP/00019). MAi, KK, FS: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project-ID 251654672 - TRR 161 and under Germany’s Excellence Strategy - EXC 2117 - 422037984. FM: “5 per 1000–2021” grant of the Italian Ministry of Health (Grant No. 5M-2021-23683787) and European Commission with HORIZON programme, BY-COVID project (Grant No. 101046203—BY-COVID). National Institute for Infectious Diseases Lazzaro Spallanzani–IRCCS received financial support from the Italian Ministry of Health grant “Ricerca Corrente”. JP, LF: IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA:964537 RISKHUNT3R]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). AMo, MP and AV acknowledge the support of the European Commission under the INFORE project (H2020-ICT-825070) and the PerMedCoE (H2020-ICT-951773). Contributions by TH and BLP were supported by NIH grant #R35GM119770 to TH. MaGo acknowledges funding from Deutsche Forschungsgemeinschaft (DFG) through grants no. 442326535 (NFDI4Health) and 451265285 (NFDI4Health Task Force COVID-19), from the European Commission through the Horizon 2020 framework program under grant no. 825843 (EU-STANDS4PM) and through the Digital Europe program under grant no. 101083771 (EDITH), as well as from the Klaus Tschira Foundation. AL acknowledges support from the Intramural Research Program of the National Library of Medicine (NLM), National Institutes of Health (NIH).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The DisGeNET knowledge platform for disease genomics: 2019 update

  • Piñero González, Janet, 1977-
  • Ramírez Anguita, Juan Manuel
  • Saüch Pitarch, Josep
  • Ronzano, Francesco
  • Centeno, Emilio
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
One of the most pressing challenges in genomic medicine is to understand the role played by genetic variation in health and disease. Thanks to the exploration of genomic variants at large scale, hundreds of thousands of disease-associated loci have been uncovered. However, the identification of variants of clinical relevance is a significant challenge that requires comprehensive interrogation of previous knowledge and linkage to new experimental results. To assist in this complex task, we created DisGeNET (http://www.disgenet.org/), a knowledge management platform integrating and standardizing data about disease associated genes and variants from multiple sources, including the scientific literature. DisGeNET covers the full spectrum of human diseases as well as normal and abnormal traits. The current release covers more than 24 000 diseases and traits, 17 000 genes and 117 000 genomic variants. The latest developments of DisGeNET include new sources of data, novel data attributes and prioritization metrics, a redesigned web interface and recently launched APIs. Thanks to the data standardization, the combination of expert curated information with data automatically mined from the scientific literature, and a suite of tools for accessing its publicly available data, DisGeNET is an interoperable resource supporting a variety of applications in genomic medicine and drug R&D., SCIII-FEDER [PI13/00082, PI17/00230, CPII16/00026]; IMI-JU resources of which are composed of financial contribution from the EU-FP7 [FP7/2007–2013] and EFPIA companies in kind contribution [116030 to TransQST, 777365 to eTRANSAFE], and the EU H2020 Programme 2014–2020 [676559 to Elixir-Excelerate]; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519]. The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and FEDER (PRB2-ISCIII [PT13/0001/0023, of the PE I+D+i 2013–2016]). The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. Funding for open access charge: Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519].
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Flame: an open source framework for model development, hosting, and usage in production environments

  • Pastor Maeso, Manuel
  • Gómez-Tamayo, José C.
  • Sanz, Ferran
This article describes Flame, an open source software for building predictive models and supporting their use in production environments. Flame is a web application with a web-based graphic interface, which can be used as a desktop application or installed in a server receiving requests from multiple users. Models can be built starting from any collection of biologically annotated chemical structures since the software supports structural normalization, molecular descriptor calculation, and machine learning model generation using predefined workflows. The model building workflow can be customized from the graphic interface, selecting the type of normalization, molecular descriptors, and machine learning algorithm to be used from a panel of state-of-the-art methods implemented natively. Moreover, Flame implements a mechanism allowing to extend its source code, adding unlimited model customization. Models generated with Flame can be easily exported, facilitating collaborative model development. All models are stored in a model repository supporting model versioning. Models are identified by unique model IDs and include detailed documentation formatted using widely accepted standards. The current version is the result of nearly 3 years of development in collaboration with users from the pharmaceutical industry within the IMI eTRANSAFE project, which aims, among other objectives, to develop high-quality predictive models based on shared legacy data for assessing the safety of drug candidates., This work has received funding from the eTRANSAFE project (Grant Agreement No. 777365), developed under the Innovative Medicines Initiative Joint Undertaking (IMI2), resources of which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in kind contributions. The authors of this article are also involved in other related IMI projects which contributed funding, such as TransQST (No. 116030) as well as the H2020 EU-ToxRisk project (No. 681002) and FAIRplus (No. 802750). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and FEDER (PT17/0009/0014). The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Application of machine learning to improve the efficiency of electrophysiological simulations used for the prediction of drug-induced ventricular arrhythmia

  • Rodríguez-Belenguer, Pablo
  • Kopańska, Karolina
  • Llopis-Lorente, Jordi
  • Trenor, Beatriz
  • Saiz, Javier
  • Pastor Maeso, Manuel
Background and objective: In silico prediction of drug-induced ventricular arrhythmia often requires computationally intensive simulations, making its application tedious and non-interactive. This inconvenience can be mitigated using matrices of precomputed simulation results, allowing instantaneous computation of biomarkers such as action potential duration at 90% of the repolarisation (APD90). However, preparing such matrices can be computationally intensive for the method developers, limiting the range of simulated conditions. In this work, we aim to optimise the generation of these matrices so that they can be obtained with less effort and for a broader range of input values. Methods: Machine learning methods were applied, building models trained with only a small fraction of the originally simulated results. The predictive performances of the models were assessed by comparing their predicted values with the actual simulation results, using percentual mean absolute error and mean relative error, as well as the percentage of data with a relative error below 5%. Results: Our method obtained highly accurate estimations of the original values, leading to a nearly one hundred-fold decrease in computation time. This method also allows precomputing more complex matrices, describing the effect of more ion channels on the APD90. The best results were obtained by applying Support Vector Machine models, which yielded errors below 1% in most cases. This approach was further validated by predicting the APD90 of a set of 12 CiPA compounds and exporting the optimal settings for predicting APD90 using a different set of ion channels, always with satisfactory results. Conclusions: The proposed method effectively reduces the computational effort required to generate matrices of precomputed electrophysiological simulation values. The same approach can be applied in other fields where computationally costly simulations are applied repeatedly using slightly different input values., The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777365, supported from European Union's Horizon 2020 and the EFPIA. We also received funding from the SimCardioTest supported by European Union’s Horizon 2020 research and innovation programme under grant agreement No 101016496. J.L.L. is being funded by the Ministerio de Ciencia, Innovacion y Universidades for the “Formacion de Profesorado Universitario” (Grant Reference: FPU18/01659). The work was also partially support by the Dirección General de Política Científica de la Generalitat Valenciana (PROMETEO/ 2020/043).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A simple framework for collaborative development of predictive models trained on proprietary data

  • Rodríguez-Belenguer, Pablo
  • Amberg, Alexander
  • Bringezu, Frank
  • Frericks, Markus
  • Hemmerich, Jennifer
  • Monecke, Peter
  • Oberhauser, Nils
  • Trairatphisan, Panuwat
  • Pastor Maeso, Manuel
We present a simple methodology that allows the building and sharing of predictive models without compromising the confidentiality of the structures of the training series. Multiple shared models can be used to obtain ensemble models, providing better coverage of the chemical space and better predictions than the original one. This approach is demonstrated in a collaborative exercise where four pharmaceutical and chemical companies developed predictive models for the AMES mutagenicity end point and shared them to build ensemble models using logical and machine learning algorithms. The results were systematically analyzed and compared, obtaining clear benefits in predictive quality. The method has the advantage of being very simple to execute, using only open-source software, and the possibility to audit the whole process and interchange files to guarantee that no confidential information is exported from the company facilities., The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777365, supported by European Union's Horizon 2020 and the EFPIA. Authors declare that this work reflects only the author's view and that IMI-JU is not responsible for any use that may be made of the information it contains.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Ensemble prediction of mitochondrial toxicity using machine learning technology

  • Bringezu, Frank
  • Gómez-Tamayo, José C.
  • Pastor Maeso, Manuel
Mitochondria are intracellular organelles found in most eukaryotic cells. Mitochondrial function includes the generation of cellular energy, maintenance of cellular homeostasis, and metabolic processes. Mitochondrial impairment has increasingly been recognized as a contributor to drug-induced toxicity. We have developed predictive models using machine learning methods for the prediction of the in vitro outcome of the MMP and the GluGal assays. These models were built using the open-source software Flame, which supports the combination of models in ensembles and the extension of the training data with further experimental data, continuously improving the predictive power of the models Despite the large amount of available data for training of models, most compounds are evaluated as negative, resulting in an imbalanced class distribution. This paper demonstrates the application of a combination of equally distributed low-level models in an ensemble to account for the imbalance in the training set resulting in a classifier providing high sensitivity and specificity of 92 and 87% respectively. The model generated can further be integrated with mechanistic in vitro data for improved screening for mitochondrial toxicity., This research was funded from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreements eTRANSAFE (777365). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA companies in kind contribution.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Functional genomics analysis to disentangle the role of genetic variants in major depression

  • Pérez-Granado, Judith
  • Piñero González, Janet, 1977-
  • Medina-Rivera, Alejandra
  • Furlong, Laura I., 1971-
Understanding the molecular basis of major depression is critical for identifying new potential biomarkers and drug targets to alleviate its burden on society. Leveraging available GWAS data and functional genomic tools to assess regulatory variation could help explain the role of major depression-associated genetic variants in disease pathogenesis. We have conducted a fine-mapping analysis of genetic variants associated with major depression and applied a pipeline focused on gene expression regulation by using two complementary approaches: cis-eQTL colocalization analysis and alteration of transcription factor binding sites. The fine-mapping process uncovered putative causally associated variants whose proximal genes were linked with major depression pathophysiology. Four colocalizing genetic variants altered the expression of five genes, highlighting the role of SLC12A5 in neuronal chlorine homeostasis and MYRF in nervous system myelination and oligodendrocyte differentiation. The transcription factor binding analysis revealed the potential role of rs62259947 in modulating P4HTM expression by altering the YY1 binding site, altogether regulating hypoxia response. Overall, our pipeline could prioritize putative causal genetic variants in major depression. More importantly, it can be applied when only index genetic variants are available. Finally, the presented approach enabled the proposal of mechanistic hypotheses of these genetic variants and their role in disease pathogenesis., IMI2-JU resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 116030 TransQST and GA: 777365 eTRANSAFE], and the EU H2020 Programme 2014–2020 [GA: 676559 Elixir-Excelerate]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519], and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII [PT13/0001/0023, of the PE I + D + i 2013–2016]). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. AMR was supported by CONACYT-FORDECYT-PRONACES grant no. [11311], and Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica–Universidad Nacional Autónoma de México (PAPIIT-UNAM) grant nos. IA203021. JPG was supported by Instituto de Salud Carlos III-Fondo Social Europeo [FI18/00034]; Instituto de Salud Carlos III [MV20]. This work reflects only the author’s view and that the IMI2-JU is not responsible for any use that may be made of the information it contains.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Collaborative SAR modeling and prospective in vitro validation of oxidative stress activation in human HepG2 cells

  • Béquignon, Olivier J. M.
  • Gómez-Tamayo, José C.
  • Lenselink, Eelke B.
  • Wink, Steven
  • Hiemstra, Steven
  • Lam, Chi Chung
  • Gadaleta, Domenico
  • Roncaglioni, Alessandra
  • Norinder, Ulf
  • van de Water, Bob
  • Pastor Maeso, Manuel
  • van Westen, Gerard J. P.
Oxidative stress is the consequence of an abnormal increase of reactive oxygen species (ROS). ROS are generated mainly during the metabolism in both normal and pathological conditions as well as from exposure to xenobiotics. Xenobiotics can, on the one hand, disrupt molecular machinery involved in redox processes and, on the other hand, reduce the effectiveness of the antioxidant activity. Such dysregulation may lead to oxidative damage when combined with oxidative stress overpassing the cell capacity to detoxify ROS. In this work, a green fluorescent protein (GFP)-tagged nuclear factor erythroid 2-related factor 2 (NRF2)-regulated sulfiredoxin reporter (Srxn1-GFP) was used to measure the antioxidant response of HepG2 cells to a large series of drug and drug-like compounds (2230 compounds). These compounds were then classified as positive or negative depending on cellular response and distributed among different modeling groups to establish structure-activity relationship (SAR) models. A selection of models was used to prospectively predict oxidative stress induced by a new set of compounds subsequently experimentally tested to validate the model predictions. Altogether, this exercise exemplifies the different challenges of developing SAR models of a phenotypic cellular readout, model combination, chemical space selection, and results interpretation., This project received funding from the EU-ToxRisk and RISK-HUNT3R projects, which received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement Nos. 681002 and 964537, respectively, and was part of the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777365 (eTRANSAFE) receiving support from the European Union’s Horizon 2020 research and innovation program and EFPIA. Additional funding was received from the VHP4Safety project, a research project funded by the Netherlands Research Council (NWO) “Netherlands Research Agenda: Research on Routes by Consortia” (NWA-ORC 1292.19.272). The authors declare that this work reflects only the author’s view and that the Innovative Medicines Initiative 2 Joint Undertaking and NWO are not responsible for any use that may be made of the information it contains.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The eTRANSAFE project on translational safety assessment through integrative knowledge management: achievements and perspectives

  • Pognan, François
  • Centeno, Emilio
  • Furlong, Laura I., 1971-
  • Guney, Emre
  • Mayer, Miguel Ángel, 1960-
  • Pastor Maeso, Manuel
  • Piñero González, Janet, 1977-
  • Ramírez Anguita, Juan Manuel
  • Ronzano, Francesco
  • Saüch Pitarch, Josep
  • Sanz, Ferran
eTRANSAFE is a research project funded within the Innovative Medicines Initiative (IMI), which aims at developing integrated databases and computational tools (the eTRANSAFE ToxHub) that support the translational safety assessment of new drugs by using legacy data provided by the pharmaceutical companies that participate in the project. The project objectives include the development of databases containing preclinical and clinical data, computational systems for translational analysis including tools for data query, analysis and visualization, as well as computational models to explain and predict drug safety events., This research received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreements eTRANSAFE (777365). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA companies in kind contribution.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Development of an infrastructure for the prediction of biological endpoints in industrial environments. Lessons learned at the eTOX Project

  • Pastor Maeso, Manuel
  • Quintana, Jordi
  • Sanz, Ferran
In silico methods are increasingly being used for assessing the chemical safety of substances, as a part of integrated approaches involving in vitro and in vivo experiments. A paradigmatic example of these strategies is the eTOX project http://www.etoxproject.eu, funded by the European Innovative Medicines Initiative (IMI), which aimed at producing high quality predictions of in vivo toxicity of drug candidates and resulted in generating about 200 models for diverse endpoints of toxicological interest. In an industry-oriented project like eTOX, apart from the predictive quality, the models need to meet other quality parameters related to the procedures for their generation and their intended use. For example, when the models are used for predicting the properties of drug candidates, the prediction system must guarantee the complete confidentiality of the compound structures. The interface of the system must be designed to provide non-expert users all the information required to choose the models and appropriately interpret the results. Moreover, procedures like installation, maintenance, documentation, validation and versioning, which are common in software development, must be also implemented for the models and for the prediction platform in which they are implemented. In this article we describe our experience in the eTOX project and the lessons learned after 7 years of close collaboration between industrial and academic partners. We believe that some of the solutions found and the tools developed could be useful for supporting similar initiatives in the future., The eTOX project (Grant Agreement No. 115002), was developed under the Innovative Medicines Initiative Joint Undertaking (IMI), resources of which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contributions. The authors of this article are also involved in other related IMI projects, such as iPiE (no. 115735), TransQST (no. 116030) and eTRANSAFE (no. 777365), as well as the H2020 EU-ToxRisk project (no. 681002)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Uncertainty assessment of proarrhythmia predictions derived from multi-level in silico models

  • Kopanska, Karolina
  • Rodriguez-Belenguer, Pablo
  • Llopis-Lorente, Jordi
  • Pastor, Manuel
  • Trenor Gomis, Beatriz Ana|||0000-0001-9166-6112
  • Saiz Rodríguez, Francisco Javier|||0000-0002-9850-0825
[EN] In silico methods can be used for an early assessment of arrhythmogenic properties of drug candidates. However, their use for decision-making is conditioned by the possibility to estimate the predictions' uncertainty. This work describes our efforts to develop uncertainty quantification methods for the predictions produced by multi-level proarrhythmia models. In silico models used in this field usually start with experimental or predicted IC50 values that describe drug-induced ion channel blockade. Using such inputs, an electrophysiological model computes how the ion channel inhibition, exerted by a drug in a certain concentration, translates to an altered shape and duration of the action potential in cardiac cells, which can be represented as arrhythmogenic risk biomarkers such as the APD(90). Using this framework, we identify the main sources of aleatory and epistemic uncertainties and propose a method based on probabilistic simulations that replaces single-point estimates predicted using multiple input values, including the IC(50)s and the electrophysiological parameters, by distributions of values. Two selected variability types associated with these inputs are then propagated through the multi-level model to estimate their impact on the uncertainty levels in the output, expressed by means of intervals. The proposed approach yields single predictions of arrhythmogenic risk biomarkers together with value intervals, providing a more comprehensive and realistic description of drug effects on a human population. The methodology was tested by predicting arrhythmogenic biomarkers on a series of twelve well-characterised marketed drugs, belonging to different arrhythmogenic risk classes., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 777365, supported from European Union s Horizon 2020 and the EFPIA. Authors declare that this work refects only the author s view, and that IMI-JU is not responsible for any use that may be made of the information it contains. Also, this project received funding from the European Union s Horizon 2020 Research and Innovation programme under Grant Agreement No. 964537 (RISK-HUNT3R), which is part of the ASPIS cluster. We also received funding from the SimCardioTest supported by European Union s Horizon 2020 research and innovation programme under Grant Agreement No. 101016496. J.L.L. is being funded by the Ministerio de Ciencia, Innovacion y Universidades for the Formacion de Profesorado Universitario (Grant Reference: FPU18/01659). The work was also partially support by the Dirección General de Política Científca de la Generalitat Valenciana (PROMETEO/2020/043).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Application of Machine Learning to improve the efficiency of electrophysiological simulations used for the prediction of drug-induced ventricular arrhythmia

  • Rodriguez-Belenguer, Pablo
  • Kopanska, Karolina
  • Llopis-Lorente, Jordi
  • Pastor, Manuel
  • Trenor Gomis, Beatriz Ana|||0000-0001-9166-6112
  • Saiz Rodríguez, Francisco Javier|||0000-0002-9850-0825
[EN] Background and Objective In silico prediction of drug-induced ventricular arrhythmia often requires computationally intensive simulations, making its application tedious and non-interactive. This inconvenience can be mitigated using matrices of precomputed simulation results, allowing instantaneous computation of biomarkers such as action potential duration at 90% of the repolarisation (APD90). However, preparing such matrices can be computationally intensive for the method developers, limiting the range of simulated conditions. In this work, we aim to optimise the generation of these matrices so that they can be obtained with less effort and for a broader range of input values. Methods Machine learning methods were applied, building models trained with only a small fraction of the originally simulated results. The predictive performances of the models were assessed by comparing their predicted values with the actual simulation results, using percentual mean absolute error and mean relative error, as well as the percentage of data with a relative error below 5%. Results Our method obtained highly accurate estimations of the original values, leading to a nearly one hundred-fold decrease in computation time. This method also allows precomputing more complex matrices, describing the effect of more ion channels on the APD90. The best results were obtained by applying Support Vector Machine models, which yielded errors below 1% in most cases. This approach was further validated by predicting the APD90 of a set of 12 CiPA compounds and exporting the optimal settings for predicting APD90 using a different set of ion channels, always with satisfactory results. Conclusions The proposed method effectively reduces the computational effort required to generate matrices of precomputed electrophysiological simulation values. The same approach can be applied in other fields where computationally costly simulations are applied repeatedly using slightly different input values., The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777365, supported from European Union's Horizon 2020 and the EFPIA. We also received funding from the SimCardioTest supported by European Union¿s Horizon 2020 research and innovation programme under grant agreement No 101016496. J.L.L. is being funded by the Ministerio de Ciencia, Innovacion y Universidades for the Formacion de Profesorado Universitario (Grant Reference: FPU18/01659). The work was also partially support by the Dirección General de Política Científica de la Generalitat Valenciana (PROMETEO/ 2020/043).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Datos de investigación Set de datos (Dataset)

Uncertainty Assessment of Proarrhythmia Predictions Derived from Multi-Level in Silico Models

  • Kopanska, Karolina
  • Rodríguez-Belenguer, Pablo
  • Llopis-Lorente, Jordi
  • Pastor, Manuel
  • Trenor Gomis, Beatriz Ana|||0000-0001-9166-6112
  • Saiz Rodríguez, Francisco Javier|||0000-0002-9850-0825
[EN] These datasets were generated to train ("PopulationDrugsTrainingKrNaLCaL.xlsx") and test ("PopulationDrugsTestKrCaLNaL.xlsx") the uncertainty assessment models developed in the paper "Uncertainty assessment of proarrhythmia predictions derived from multi-level in silico models" by Kopanska, Rodríguez-Belenguer, et al., The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777365, supported from European Union's Horizon 2020 and the EFPIA. We also received funding from the SimCardioTest supported by European Union’s Horizon 2020 research and innovation programme under grant agreement No 101016496. J.L.L. is being funded by the Ministerio de Ciencia, Innovacion y Universidades for the “Formacion de Profesorado Universitario” (Grant Reference: FPU18/01659). The work was also partially support by the Dirección General de Política Científica de la Generalitat Valenciana (PROMETEO/ 2020/043).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches

  • Niarakis, Anna
  • Ostaszewski, Marek
  • Mazein, Alexander
  • Kuperstein, Inna
  • Kutmon, Martina
  • Gillespie, Marc E.
  • Funahashi, Akira
  • Acencio, Marcio Luis
  • Hemedan, Ahmed
  • Aichem, Michael
  • Klein, Karsten
  • Czauderna, Tobias
  • Burtscher, Felicia
  • Yamada, Takahiro G.
  • Hiki, Yusuke
  • Hiroi, Noriko F.
  • Hu, Finterly
  • Pham, Nhung
  • Ehrhart, Friederike
  • Willighagen, Egon L.
  • Valdeolivas, Alberto
  • Dugourd, Aurelien
  • Messina, Francesco
  • Esteban-Medina, Marina
  • Peña-Chilet, María
  • Rian, Kinza
  • Soliman, Sylvain
  • Aghamiri, Sara Sadat
  • Lal Puniya, Bhanwar
  • Naldi, Aurelien
  • Helikar, Tomas
  • Singh, Vidisha
  • Fariñas Fernández, Marco
  • Bermudez, Viviam
  • Tsirvouli, Eirini
  • Montagud, Arnau
  • Noël, Vincent
  • Ponce de León, Miguel
  • Maier, Dieter
  • Bauch, Angela
  • Gyori, Benjamin M.
  • Bachman, John A.
  • Luna, Augustin
  • Piñero, Janet
  • Furlong, Laura I.
  • Balaur, Irina BalaurIrina
  • Rougny, Adrien
  • Jarosz, Yohan
  • Overall, Rupert W.
  • Phair, Robert
  • Perfetto, Livia
  • Matthews, Lisa
  • Balaya Rex, Devasahayam Arokia
  • Orlic-Milacic, Marija
  • Monraz Gómez, Luis Cristóbal
  • De Meulder, Bertrand
  • Ravel, Jean-Marie
  • Jassal, Bijay
  • Satagopam, Venkata
  • Wu, Guanming
  • Golebiewski, Martin
  • Gawron, Piotr
  • Calzone, Laurence
  • Beckmann, Jacques S.
  • Evelo, Chris T.
  • D’Eustachio, Peter
  • Schreiber, Falk
  • Sáez-Rodríguez, Julio
  • Dopazo, Joaquín
  • Kuiper, Martin
  • Valencia, Alfonso
  • Wolkenhauer, Olaf
  • Kitano, Hiroaki
  • Barillot, Emmanuel
  • Auffray, Charles
  • Balling, Rudi
  • Schneider, Reinhard
  • COVID- Disease Map Community the COVID-19 Disease Map Community
© 2024 Niarakis, Ostaszewski, Mazein, Kuperstein, Kutmon, Gillespie, Funahashi, Acencio, Hemedan, Aichem, Klein, Czauderna, Burtscher, Yamada, Hiki, Hiroi, Hu, Pham, Ehrhart, Willighagen, Valdeolivas, Dugourd, Messina, Esteban-Medina, Peña-Chilet, Rian, Soliman, Aghamiri, Puniya, Naldi, Helikar, Singh, Fernández, Bermudez, Tsirvouli, Montagud, Noël, Ponce-de-Leon, Maier, Bauch, Gyori, Bachman, Luna, Piñero, Furlong, Balaur, Rougny, Jarosz, Overall, Phair, Perfetto, Matthews, Rex, Orlic-Milacic, Gomez, De Meulder, Ravel, Jassal, Satagopam, Wu, Golebiewski, Gawron, Calzone, Beckmann, Evelo, D’Eustachio, Schreiber, Saez-Rodriguez, Dopazo, Kuiper, Valencia, Wolkenhauer, Kitano, Barillot, Auffray, Balling, Schneider and the COVID-19 Disease Map Community. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms., Introduction: The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing., Methods: Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue- or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors., Results: Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19., Discussion: The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. AN acknowledges support from SANOFI-AVENTIS R&D via the CIFRE contract, n° 2020/0766. MK, FH, NP, FE, and CE acknowledge the support of the ZonMw COVID-19 programme (Grant No. 10430012010015). JD Spanish Ministry of Science and Innovation (Grant no. PID2020-117979RB-I00) and Instituto de Salud Carlos III (Grant no. IMP/00019). MAi, KK, FS: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project-ID 251654672 - TRR 161 and under Germany’s Excellence Strategy - EXC 2117 - 422037984. FM: “5 per 1000–2021” grant of the Italian Ministry of Health (Grant No. 5M-2021-23683787) and European Commission with HORIZON programme, BY-COVID project (Grant No. 101046203—BY-COVID). National Institute for Infectious Diseases Lazzaro Spallanzani–IRCCS received financial support from the Italian Ministry of Health grant “Ricerca Corrente”. JP, LF: IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA:964537 RISKHUNT3R]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). AMo, MP and AV acknowledge the support of the European Commission under the INFORE project (H2020-ICT-825070) and the PerMedCoE (H2020-ICT-951773). Contributions by TH and BLP were supported by NIH grant #R35GM119770 to TH. MaGo acknowledges funding from Deutsche Forschungsgemeinschaft (DFG) through grants no. 442326535 (NFDI4Health) and 451265285 (NFDI4Health Task Force COVID-19), from the European Commission through the Horizon 2020 framework program under grant no. 825843 (EU-STANDS4PM) and through the Digital Europe program under grant no. 101083771 (EDITH), as well as from the Klaus Tschira Foundation. AL acknowledges support from the Intramural Research Program of the National Library of Medicine (NLM), National Institutes of Health (NIH)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Integrating mechanistic and toxicokinetic information in predictive models of cholestasis

  • Rodríguez-Belenguer, Pablo
  • Mangas Sanjuan, Victor
  • Soria Olivas, Emilio
  • Pastor Maeso, Manuel
Drug development involves the thorough assessment of the candidate's safety and efficacy. In silico toxicology (IST) methods can contribute to the assessment, complementing in vitro and in vivo experimental methods, since they have many advantages in terms of cost and time. Also, they are less demanding concerning the requirements of product and experimental animals. One of these methods, Quantitative Structure-Activity Relationships (QSAR), has been proven successful in predicting simple toxicity end points but has more difficulties in predicting end points involving more complex phenomena. We hypothesize that QSAR models can produce better predictions of these end points by combining multiple QSAR models describing simpler biological phenomena and incorporating pharmacokinetic (PK) information, using quantitative in vitro to in vivo extrapolation (QIVIVE) models. In this study, we applied our methodology to the prediction of cholestasis and compared it with direct QSAR models. Our results show a clear increase in sensitivity. The predictive quality of the models was further assessed to mimic realistic conditions where the query compounds show low similarity with the training series. Again, our methodology shows clear advantages over direct QSAR models in these situations. We conclude that the proposed methodology could improve existing methodologies and could be suitable for being applied to other toxicity end points., The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777365, European Union’s Horizon 2020, and EFPIA. The authors declare that this work reflects only the author’s view and that IMI-JU is not responsible for any use that may be made of the information it contains. Also, this project received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 964537 (RISK-HUNT3R), which is part of the ASPIS cluster.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Uncertainty assessment of proarrhythmia predictions derived from multi-level in silico models

  • Kopańska, Karolina
  • Rodríguez-Belenguer, Pablo
  • Llopis-Lorente, Jordi
  • Trenor, Beatriz
  • Saiz, Javier
  • Pastor Maeso, Manuel
In silico methods can be used for an early assessment of arrhythmogenic properties of drug candidates. However, their use for decision-making is conditioned by the possibility to estimate the predictions' uncertainty. This work describes our efforts to develop uncertainty quantification methods for the predictions produced by multi-level proarrhythmia models. In silico models used in this field usually start with experimental or predicted IC50 values that describe drug-induced ion channel blockade. Using such inputs, an electrophysiological model computes how the ion channel inhibition, exerted by a drug in a certain concentration, translates to an altered shape and duration of the action potential in cardiac cells, which can be represented as arrhythmogenic risk biomarkers such as the APD90. Using this framework, we identify the main sources of aleatory and epistemic uncertainties and propose a method based on probabilistic simulations that replaces single-point estimates predicted using multiple input values, including the IC50s and the electrophysiological parameters, by distributions of values. Two selected variability types associated with these inputs are then propagated through the multi-level model to estimate their impact on the uncertainty levels in the output, expressed by means of intervals. The proposed approach yields single predictions of arrhythmogenic risk biomarkers together with value intervals, providing a more comprehensive and realistic description of drug effects on a human population. The methodology was tested by predicting arrhythmogenic biomarkers on a series of twelve well-characterised marketed drugs, belonging to different arrhythmogenic risk classes., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 777365, supported from European Union’s Horizon 2020 and the EFPIA. Authors declare that this work reflects only the author’s view, and that IMI-JU is not responsible for any use that may be made of the information it contains. Also, this project received funding from the European Union’s Horizon 2020 Research and Innovation programme under Grant Agreement No. 964537 (RISK-HUNT3R), which is part of the ASPIS cluster. We also received funding from the SimCardioTest supported by European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 101016496. J.L.L. is being funded by the Ministerio de Ciencia, Innovacion y Universidades for the “Formacion de Profesorado Universitario” (Grant Reference: FPU18/01659). The work was also partially support by the Dirección General de Política Científica de la Generalitat Valenciana (PROMETEO/2020/043).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Collaborative SAR modeling and prospective in vitro validation of oxidative stress activation in human HepG2 cells

  • Béquignon, Olivier J. M.
  • Gómez-Tamayo, José C.
  • Lenselink, Eelke B.
  • Wink, Steven
  • Hiemstra, Steven
  • Lam, Chi Chung
  • Gadaleta, Domenico
  • Roncaglioni, Alessandra
  • Norinder, Ulf
  • van de Water, Bob
  • Pastor Maeso, Manuel
  • van Westen, Gerard J. P.
Oxidative stress is the consequence of an abnormal increase of reactive oxygen species (ROS). ROS are generated mainly during the metabolism in both normal and pathological conditions as well as from exposure to xenobiotics. Xenobiotics can, on the one hand, disrupt molecular machinery involved in redox processes and, on the other hand, reduce the effectiveness of the antioxidant activity. Such dysregulation may lead to oxidative damage when combined with oxidative stress overpassing the cell capacity to detoxify ROS. In this work, a green fluorescent protein (GFP)-tagged nuclear factor erythroid 2-related factor 2 (NRF2)-regulated sulfiredoxin reporter (Srxn1-GFP) was used to measure the antioxidant response of HepG2 cells to a large series of drug and drug-like compounds (2230 compounds). These compounds were then classified as positive or negative depending on cellular response and distributed among different modeling groups to establish structure-activity relationship (SAR) models. A selection of models was used to prospectively predict oxidative stress induced by a new set of compounds subsequently experimentally tested to validate the model predictions. Altogether, this exercise exemplifies the different challenges of developing SAR models of a phenotypic cellular readout, model combination, chemical space selection, and results interpretation., This project received funding from the EU-ToxRisk and RISK-HUNT3R projects, which received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement Nos. 681002 and 964537, respectively, and was part of the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777365 (eTRANSAFE) receiving support from the European Union’s Horizon 2020 research and innovation program and EFPIA. Additional funding was received from the VHP4Safety project, a research project funded by the Netherlands Research Council (NWO) “Netherlands Research Agenda: Research on Routes by Consortia” (NWA-ORC 1292.19.272). The authors declare that this work reflects only the author’s view and that the Innovative Medicines Initiative 2 Joint Undertaking and NWO are not responsible for any use that may be made of the information it contains.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Guidelines for FAIR sharing of preclinical safety and off-target pharmacology data

  • Briggs, Katharine
  • Bosc, Nicolas
  • Camara, Tima
  • Diaz, Carlos
  • Drew, Phil
  • Drewe, William C.
  • Kors, Jan A.
  • Mulligen, Erik van
  • Pastor Maeso, Manuel
  • Pognan, François
  • Quintana, Jordi
  • Sarntivijai, Sirarat
  • Steger-Hartmann, Thomas
Pre-competitive data sharing can offer the pharmaceutical industry significant benefits in terms of reducing the time and costs involved in getting a new drug to market through more informed testing strategies and knowledge gained by pooling data. If sufficient data is shared and can be co-analyzed, then it can also offer the potential for reduced animal usage and improvements in the in silico prediction of toxicological effects. Data sharing benefits can be further enhanced by applying the FAIR Guiding Principles, reducing time spent curating, transforming and aggregating datasets and allowing more time for data mining and analysis. We hope to facilitate data sharing by other organizations and initiatives by describing lessons learned as part of the Enhancing TRANslational SAFEty Assessment through Integrative Knowledge Management (eTRANSAFE) project, an Innovative Medicines Initiative (IMI) partnership which aims to integrate publicly available data sources with proprietary preclinical and clinical data donated by pharmaceutical organizations. Methods to foster trust and overcome non-technical barriers to data sharing such as legal and IPR (intellectual property rights) are described, including the security requirements that pharmaceutical organizations generally expect to be met. We share the consensus achieved among pharmaceutical partners on decision criteria to be included in internal clearance procedures used to decide if data can be shared. We also report on the consensus achieved on specific data fields to be excluded from sharing for sensitive preclinical safety and pharmacology data that could otherwise not be shared., This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777365 (“eTRANSAFE”). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Development of an infrastructure for the prediction of biological endpoints in industrial environments. Lessons learned at the eTOX Project

  • Pastor Maeso, Manuel
  • Quintana, Jordi
  • Sanz, Ferran
In silico methods are increasingly being used for assessing the chemical safety of substances, as a part of integrated approaches involving in vitro and in vivo experiments. A paradigmatic example of these strategies is the eTOX project http://www.etoxproject.eu, funded by the European Innovative Medicines Initiative (IMI), which aimed at producing high quality predictions of in vivo toxicity of drug candidates and resulted in generating about 200 models for diverse endpoints of toxicological interest. In an industry-oriented project like eTOX, apart from the predictive quality, the models need to meet other quality parameters related to the procedures for their generation and their intended use. For example, when the models are used for predicting the properties of drug candidates, the prediction system must guarantee the complete confidentiality of the compound structures. The interface of the system must be designed to provide non-expert users all the information required to choose the models and appropriately interpret the results. Moreover, procedures like installation, maintenance, documentation, validation and versioning, which are common in software development, must be also implemented for the models and for the prediction platform in which they are implemented. In this article we describe our experience in the eTOX project and the lessons learned after 7 years of close collaboration between industrial and academic partners. We believe that some of the solutions found and the tools developed could be useful for supporting similar initiatives in the future., The eTOX project (Grant Agreement No. 115002), was developed under the Innovative Medicines Initiative Joint Undertaking (IMI), resources of which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contributions. The authors of this article are also involved in other related IMI projects, such as iPiE (no. 115735), TransQST (no. 116030) and eTRANSAFE (no. 777365), as well as the H2020 EU-ToxRisk project (no. 681002)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

PretoxTM: a text mining system for extracting treatment-related findings from preclinical toxicology reports

  • Corvi, Javier
  • Ronzano, Francesco
  • Centeno, Emilio
  • Capella Gutiérrez, Salvador Jesús, 1985-
Over the last few decades the pharmaceutical industry has generated a vast corpus of knowledge on the safety and efficacy of drugs. Much of this information is contained in toxicology reports, which summarise the results of animal studies designed to analyse the effects of the tested compound, including unintended pharmacological and toxic effects, known as treatment-related findings. Despite the potential of this knowledge, the fact that most of this relevant information is only available as unstructured text with variable degrees of digitisation has hampered its systematic access, use and exploitation. Text mining technologies have the ability to automatically extract, analyse and aggregate such information, providing valuable new insights into the drug discovery and development process. In the context of the eTRANSAFE project, we present PretoxTM (Preclinical Toxicology Text Mining), the first system specifically designed to detect, extract, organise and visualise treatment-related findings from toxicology reports. The PretoxTM tool comprises three main components: PretoxTM Corpus, PretoxTM Pipeline and PretoxTM Web App. The PretoxTM Corpus is a gold standard corpus of preclinical treatment-related findings annotated by toxicology experts. This corpus was used to develop, train and validate the PretoxTM Pipeline, which extracts treatment-related findings from preclinical study reports. The extracted information is then presented for expert visualisation and validation in the PretoxTM Web App. Scientific Contribution While text mining solutions have been widely used in the clinical domain to identify adverse drug reactions from various sources, no similar systems exist for identifying adverse events in animal models during preclinical testing. PretoxTM fills this gap by efficiently extracting treatment-related findings from preclinical toxicology reports. This provides a valuable resource for toxicology research, enhancing the efficiency of safety evaluations, saving time, and leading to more effective decision-making in the drug development process., JC was partly supported by eTRANSAFE (received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777365 and support from the European Union's Horizon 2020 research and innovation programme and EFPIA).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Generating modeling data from repeat-dose toxicity reports

  • López Massaguer, Oriol, 1972-
  • Pinto Gil, Kevin
  • Sanz, Ferran
  • Amberg, Alexander
  • Anger, Lennart T.
  • Stolte, Manuela
  • Ravagli, Carlo
  • Marc, Philippe
  • Pastor Maeso, Manuel
Over the past decades, pharmaceutical companies have conducted a large number of high-quality in vivo repeat-dose toxicity (RDT) studies for regulatory purposes. As part of the eTOX project, a high number of these studies have been compiled and integrated into a database. This valuable resource can be queried directly, but it can be further exploited to build predictive models. As the studies were originally conducted to investigate the properties of individual compounds, the experimental conditions across the studies are highly heterogeneous. Consequently, the original data required normalization/standardization, filtering, categorization and integration to make possible any data analysis (such as building predictive models). Additionally, the primary objectives of the RDT studies were to identify toxicological findings, most of which do not directly translate to in vivo endpoints. This article describes a method to extract datasets containing comparable toxicological properties for a series of compounds amenable for building predictive models. The proposed strategy starts with the normalization of the terms used within the original reports. Then, comparable datasets are extracted from the database by applying filters based on the experimental conditions. Finally, carefully selected profiles of toxicological findings are mapped to endpoints of interest, generating QSAR-like tables. In this work, we describe in detail the strategy and tools used for carrying out these transformations and illustrate its application in a data sample extracted from the eTOX database. The suitability of the resulting tables for developing hazard-predicting models was investigated by building proof-of-concept models for in vivo liver endpoints., Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115002 (eTOX), resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contributions. Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 777365 (eTRANSAFE). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA companies' in-kind contributions.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Flame: an open source framework for model development, hosting, and usage in production environments

  • Pastor Maeso, Manuel
  • Gómez-Tamayo, José C.
  • Sanz, Ferran
This article describes Flame, an open source software for building predictive models and supporting their use in production environments. Flame is a web application with a web-based graphic interface, which can be used as a desktop application or installed in a server receiving requests from multiple users. Models can be built starting from any collection of biologically annotated chemical structures since the software supports structural normalization, molecular descriptor calculation, and machine learning model generation using predefined workflows. The model building workflow can be customized from the graphic interface, selecting the type of normalization, molecular descriptors, and machine learning algorithm to be used from a panel of state-of-the-art methods implemented natively. Moreover, Flame implements a mechanism allowing to extend its source code, adding unlimited model customization. Models generated with Flame can be easily exported, facilitating collaborative model development. All models are stored in a model repository supporting model versioning. Models are identified by unique model IDs and include detailed documentation formatted using widely accepted standards. The current version is the result of nearly 3 years of development in collaboration with users from the pharmaceutical industry within the IMI eTRANSAFE project, which aims, among other objectives, to develop high-quality predictive models based on shared legacy data for assessing the safety of drug candidates., This work has received funding from the eTRANSAFE project (Grant Agreement No. 777365), developed under the Innovative Medicines Initiative Joint Undertaking (IMI2), resources of which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in kind contributions. The authors of this article are also involved in other related IMI projects which contributed funding, such as TransQST (No. 116030) as well as the H2020 EU-ToxRisk project (No. 681002) and FAIRplus (No. 802750). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and FEDER (PT17/0009/0014). The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identifying multiscale translational safety biomarkers using a network-based systems approach

  • Callegaro, Giulia
  • Schimming, Johannes P.
  • Piñero González, Janet, 1977-
  • Kunnen, Steven J.
  • Wijaya, Lukas
  • Trairatphisan, Panuwat
  • van den Berk, Linda
  • Beetsma, Kim
  • Furlong, Laura I.
  • Sutherland, Jeffrey J.
  • Mollon, Jennifer
  • Stevens, James L.
  • van de Water, Bob
Animal testing is the current standard for drug and chemicals safety assessment, but hazards translation to human is uncertain. Human in vitro models can address the species translation but might not replicate in vivo complexity. Herein, we propose a network-based method addressing these translational multiscale problems that derives in vivo liver injury biomarkers applicable to in vitro human early safety screening. We applied weighted correlation network analysis (WGCNA) to a large rat liver transcriptomic dataset to obtain co-regulated gene clusters (modules). We identified modules statistically associated with liver pathologies, including a module enriched for ATF4-regulated genes as associated with the occurrence of hepatocellular single-cell necrosis, and as preserved in human liver in vitro models. Within the module, we identified TRIB3 and MTHFD2 as a novel candidate stress biomarkers, and developed and used BAC-eGFPHepG2 reporters in a compound screening, identifying compounds showing ATF4-dependent stress response and potential early safety signals., This work was supported by the EU-EFPIA Innovative Medicines Initiative 2 (IMI2) Joint Undertaking TransQST project (grant number 116030) and eTRANSAFE project (grant number 777365) (this Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA), the EC Horizon2020 EU-ToxRisk project (grant number 681002), the European Research & Innovation project funded under the European Commission’s Horizon 2020 program RISK-HUNT3R project (grant number 964537) and the Cosmetics Europe/CEFIC Liver Ontology project.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Making in silico predictive models for toxicology FAIR

  • Cronin, Mark T. D.
  • Belfield, Samuel J.
  • Briggs, Katharine
  • Enoch, Steven J.
  • Firman, James W.
  • Frericks, Markus
  • Garrard, Clare
  • Maccallum, Peter H.
  • Madden, Judith C.
  • Pastor Maeso, Manuel
  • Sanz, Ferran
  • Soininen, Inari
  • Sousoni, Despoina
In silico predictive models for toxicology include quantitative structure-activity relationship (QSAR) and physiologically based kinetic (PBK) approaches to predict physico-chemical and ADME properties, toxicological effects and internal exposure. Such models are used to fill data gaps as part of chemical risk assessment. There is a growing need to ensure in silico predictive models for toxicology are available for use and that they are reproducible. This paper describes how the FAIR (Findable, Accessible, Interoperable, Reusable) principles, developed for data sharing, have been applied to in silico predictive models. In particular, this investigation has focussed on how the FAIR principles could be applied to improved regulatory acceptance of predictions from such models. Eighteen principles have been developed that cover all aspects of FAIR. It is intended that FAIRification of in silico predictive models for toxicology will increase their use and acceptance., This research received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) under grant agreement eTRANSAFE (777365), the European Union’s Horizon 2020 ELIXIR-CONVERGE Project (871075) and research and innovation programme under grant agreement No 964537 (RISK-HUNT3R).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Application of machine learning to improve the efficiency of electrophysiological simulations used for the prediction of drug-induced ventricular arrhythmia

  • Rodríguez-Belenguer, Pablo
  • Kopańska, Karolina
  • Llopis-Lorente, Jordi
  • Trenor, Beatriz
  • Saiz, Javier
  • Pastor Maeso, Manuel
Background and objective: In silico prediction of drug-induced ventricular arrhythmia often requires computationally intensive simulations, making its application tedious and non-interactive. This inconvenience can be mitigated using matrices of precomputed simulation results, allowing instantaneous computation of biomarkers such as action potential duration at 90% of the repolarisation (APD90). However, preparing such matrices can be computationally intensive for the method developers, limiting the range of simulated conditions. In this work, we aim to optimise the generation of these matrices so that they can be obtained with less effort and for a broader range of input values. Methods: Machine learning methods were applied, building models trained with only a small fraction of the originally simulated results. The predictive performances of the models were assessed by comparing their predicted values with the actual simulation results, using percentual mean absolute error and mean relative error, as well as the percentage of data with a relative error below 5%. Results: Our method obtained highly accurate estimations of the original values, leading to a nearly one hundred-fold decrease in computation time. This method also allows precomputing more complex matrices, describing the effect of more ion channels on the APD90. The best results were obtained by applying Support Vector Machine models, which yielded errors below 1% in most cases. This approach was further validated by predicting the APD90 of a set of 12 CiPA compounds and exporting the optimal settings for predicting APD90 using a different set of ion channels, always with satisfactory results. Conclusions: The proposed method effectively reduces the computational effort required to generate matrices of precomputed electrophysiological simulation values. The same approach can be applied in other fields where computationally costly simulations are applied repeatedly using slightly different input values., The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777365, supported from European Union's Horizon 2020 and the EFPIA. We also received funding from the SimCardioTest supported by European Union’s Horizon 2020 research and innovation programme under grant agreement No 101016496. J.L.L. is being funded by the Ministerio de Ciencia, Innovacion y Universidades for the “Formacion de Profesorado Universitario” (Grant Reference: FPU18/01659). The work was also partially support by the Dirección General de Política Científica de la Generalitat Valenciana (PROMETEO/ 2020/043).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Benchmarking post-GWAS analysis tools in major depression: Challenges and implications

  • Pérez-Granado, Judith
  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
Our knowledge of complex disorders has increased in the last years thanks to the identification of genetic variants (GVs) significantly associated with disease phenotypes by genome-wide association studies (GWAS). However, we do not understand yet how these GVs functionally impact disease pathogenesis or their underlying biological mechanisms. Among the multiple post-GWAS methods available, fine-mapping and colocalization approaches are commonly used to identify causal GVs, meaning those with a biological effect on the trait, and their functional effects. Despite the variety of post-GWAS tools available, there is no guideline for method eligibility or validity, even though these methods work under different assumptions when accounting for linkage disequilibrium and integrating molecular annotation data. Moreover, there is no benchmarking of the available tools. In this context, we have applied two different fine-mapping and colocalization methods to the same GWAS on major depression (MD) and expression quantitative trait loci (eQTL) datasets. Our goal is to perform a systematic comparison of the results obtained by the different tools. To that end, we have evaluated their results at different levels: fine-mapped and colocalizing GVs, their target genes and tissue specificity according to gene expression information, as well as the biological processes in which they are involved. Our findings highlight the importance of fine-mapping as a key step for subsequent analysis. Notably, the colocalizing variants, altered genes and targeted tissues differed between methods, even regarding their biological implications. This contribution illustrates an important issue in post-GWAS analysis with relevant consequences on the use of GWAS results for elucidation of disease pathobiology, drug target prioritization and biomarker discovery., IMI2-JU resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA (GA: 116030 TransQST and GA: 777365 eTRANSAFE), and the EU H2020 Programme 2014–2020 (GA: 676559 Elixir-Excelerate); Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya (2017SGR00519), and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII (PT13/0001/0023, of the PE I + D + i 2013–2016)). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO (MDM-2014-0370). JP-G was supported by Instituto de Salud Carlos III-Fondo Social Europeo (FI18/00034). This statement is a requirement from our funding agencies and therefore has to be included in the Funding section.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Ensemble prediction of mitochondrial toxicity using machine learning technology

  • Bringezu, Frank
  • Gómez-Tamayo, José C.
  • Pastor Maeso, Manuel
Mitochondria are intracellular organelles found in most eukaryotic cells. Mitochondrial function includes the generation of cellular energy, maintenance of cellular homeostasis, and metabolic processes. Mitochondrial impairment has increasingly been recognized as a contributor to drug-induced toxicity. We have developed predictive models using machine learning methods for the prediction of the in vitro outcome of the MMP and the GluGal assays. These models were built using the open-source software Flame, which supports the combination of models in ensembles and the extension of the training data with further experimental data, continuously improving the predictive power of the models Despite the large amount of available data for training of models, most compounds are evaluated as negative, resulting in an imbalanced class distribution. This paper demonstrates the application of a combination of equally distributed low-level models in an ensemble to account for the imbalance in the training set resulting in a classifier providing high sensitivity and specificity of 92 and 87% respectively. The model generated can further be integrated with mechanistic in vitro data for improved screening for mitochondrial toxicity., This research was funded from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreements eTRANSAFE (777365). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA companies in kind contribution.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches

  • Niarakis, Anna
  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
  • COVID-19 Disease Map Community
Introduction: The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing. Methods: Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue- or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors. Results: Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19. Discussion: The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. AN acknowledges support from SANOFI-AVENTIS R&D via the CIFRE contract, n° 2020/0766. MK, FH, NP, FE, and CE acknowledge the support of the ZonMw COVID-19 programme (Grant No. 10430012010015). JD Spanish Ministry of Science and Innovation (Grant no. PID2020-117979RB-I00) and Instituto de Salud Carlos III (Grant no. IMP/00019). MAi, KK, FS: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project-ID 251654672 - TRR 161 and under Germany’s Excellence Strategy - EXC 2117 - 422037984. FM: “5 per 1000–2021” grant of the Italian Ministry of Health (Grant No. 5M-2021-23683787) and European Commission with HORIZON programme, BY-COVID project (Grant No. 101046203—BY-COVID). National Institute for Infectious Diseases Lazzaro Spallanzani–IRCCS received financial support from the Italian Ministry of Health grant “Ricerca Corrente”. JP, LF: IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA:964537 RISKHUNT3R]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). AMo, MP and AV acknowledge the support of the European Commission under the INFORE project (H2020-ICT-825070) and the PerMedCoE (H2020-ICT-951773). Contributions by TH and BLP were supported by NIH grant #R35GM119770 to TH. MaGo acknowledges funding from Deutsche Forschungsgemeinschaft (DFG) through grants no. 442326535 (NFDI4Health) and 451265285 (NFDI4Health Task Force COVID-19), from the European Commission through the Horizon 2020 framework program under grant no. 825843 (EU-STANDS4PM) and through the Digital Europe program under grant no. 101083771 (EDITH), as well as from the Klaus Tschira Foundation. AL acknowledges support from the Intramural Research Program of the National Library of Medicine (NLM), National Institutes of Health (NIH).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Functional genomics analysis to disentangle the role of genetic variants in major depression

  • Pérez-Granado, Judith
  • Piñero González, Janet, 1977-
  • Medina-Rivera, Alejandra
  • Furlong, Laura I., 1971-
Understanding the molecular basis of major depression is critical for identifying new potential biomarkers and drug targets to alleviate its burden on society. Leveraging available GWAS data and functional genomic tools to assess regulatory variation could help explain the role of major depression-associated genetic variants in disease pathogenesis. We have conducted a fine-mapping analysis of genetic variants associated with major depression and applied a pipeline focused on gene expression regulation by using two complementary approaches: cis-eQTL colocalization analysis and alteration of transcription factor binding sites. The fine-mapping process uncovered putative causally associated variants whose proximal genes were linked with major depression pathophysiology. Four colocalizing genetic variants altered the expression of five genes, highlighting the role of SLC12A5 in neuronal chlorine homeostasis and MYRF in nervous system myelination and oligodendrocyte differentiation. The transcription factor binding analysis revealed the potential role of rs62259947 in modulating P4HTM expression by altering the YY1 binding site, altogether regulating hypoxia response. Overall, our pipeline could prioritize putative causal genetic variants in major depression. More importantly, it can be applied when only index genetic variants are available. Finally, the presented approach enabled the proposal of mechanistic hypotheses of these genetic variants and their role in disease pathogenesis., IMI2-JU resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 116030 TransQST and GA: 777365 eTRANSAFE], and the EU H2020 Programme 2014–2020 [GA: 676559 Elixir-Excelerate]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519], and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII [PT13/0001/0023, of the PE I + D + i 2013–2016]). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. AMR was supported by CONACYT-FORDECYT-PRONACES grant no. [11311], and Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica–Universidad Nacional Autónoma de México (PAPIIT-UNAM) grant nos. IA203021. JPG was supported by Instituto de Salud Carlos III-Fondo Social Europeo [FI18/00034]; Instituto de Salud Carlos III [MV20]. This work reflects only the author’s view and that the IMI2-JU is not responsible for any use that may be made of the information it contains.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The DisGeNET knowledge platform for disease genomics: 2019 update

  • Piñero González, Janet, 1977-
  • Ramírez Anguita, Juan Manuel
  • Saüch Pitarch, Josep
  • Ronzano, Francesco
  • Centeno, Emilio
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
One of the most pressing challenges in genomic medicine is to understand the role played by genetic variation in health and disease. Thanks to the exploration of genomic variants at large scale, hundreds of thousands of disease-associated loci have been uncovered. However, the identification of variants of clinical relevance is a significant challenge that requires comprehensive interrogation of previous knowledge and linkage to new experimental results. To assist in this complex task, we created DisGeNET (http://www.disgenet.org/), a knowledge management platform integrating and standardizing data about disease associated genes and variants from multiple sources, including the scientific literature. DisGeNET covers the full spectrum of human diseases as well as normal and abnormal traits. The current release covers more than 24 000 diseases and traits, 17 000 genes and 117 000 genomic variants. The latest developments of DisGeNET include new sources of data, novel data attributes and prioritization metrics, a redesigned web interface and recently launched APIs. Thanks to the data standardization, the combination of expert curated information with data automatically mined from the scientific literature, and a suite of tools for accessing its publicly available data, DisGeNET is an interoperable resource supporting a variety of applications in genomic medicine and drug R&D., SCIII-FEDER [PI13/00082, PI17/00230, CPII16/00026]; IMI-JU resources of which are composed of financial contribution from the EU-FP7 [FP7/2007–2013] and EFPIA companies in kind contribution [116030 to TransQST, 777365 to eTRANSAFE], and the EU H2020 Programme 2014–2020 [676559 to Elixir-Excelerate]; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519]. The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and FEDER (PRB2-ISCIII [PT13/0001/0023, of the PE I+D+i 2013–2016]). The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. Funding for open access charge: Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519].
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A simple framework for collaborative development of predictive models trained on proprietary data

  • Rodríguez-Belenguer, Pablo
  • Amberg, Alexander
  • Bringezu, Frank
  • Frericks, Markus
  • Hemmerich, Jennifer
  • Monecke, Peter
  • Oberhauser, Nils
  • Trairatphisan, Panuwat
  • Pastor Maeso, Manuel
We present a simple methodology that allows the building and sharing of predictive models without compromising the confidentiality of the structures of the training series. Multiple shared models can be used to obtain ensemble models, providing better coverage of the chemical space and better predictions than the original one. This approach is demonstrated in a collaborative exercise where four pharmaceutical and chemical companies developed predictive models for the AMES mutagenicity end point and shared them to build ensemble models using logical and machine learning algorithms. The results were systematically analyzed and compared, obtaining clear benefits in predictive quality. The method has the advantage of being very simple to execute, using only open-source software, and the possibility to audit the whole process and interchange files to guarantee that no confidential information is exported from the company facilities., The authors received funding from the eTRANSAFE project, Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777365, supported by European Union's Horizon 2020 and the EFPIA. Authors declare that this work reflects only the author's view and that IMI-JU is not responsible for any use that may be made of the information it contains.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genomic and proteomic biomarker landscape in clinical trials

  • Piñero González, Janet, 1977-
  • Rodriguez Fraga, Pablo S.
  • Valls-Margarit, Jordi
  • Ronzano, Francesco
  • Accuosto, Pablo
  • Lambea Jane, Ricard
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
The use of molecular biomarkers to support disease diagnosis, monitor its progression, and guide drug treatment has gained traction in the last decades. While only a dozen biomarkers have been approved for their exploitation in the clinic by the FDA, many more are evaluated in the context of translational research and clinical trials. Furthermore, the information on which biomarkers are measured, for which purpose, and in relation to which conditions are not readily accessible: biomarkers used in clinical studies available through resources such as ClinicalTrials.gov are described as free text, posing significant challenges in finding, analyzing, and processing them by both humans and machines. We present a text mining strategy to identify proteomic and genomic biomarkers used in clinical trials and classify them according to the methodologies by which they are measured. We find more than 3000 biomarkers used in the context of 2600 diseases. By analyzing this dataset, we uncover patterns of use of biomarkers across therapeutic areas over time, including the biomarker type and their specificity. These data are made available at the Clinical Biomarker App at https://www.disgenet.org/biomarkers/, a new portal that enables the exploration of biomarkers extracted from the clinical studies available at ClinicalTrials.gov and enriched with information from the scientific literature. The App features several metrics that assess the specificity of the biomarkers, facilitating their selection and prioritization. Overall, the Clinical Biomarker App is a valuable and timely resource about clinical biomarkers, to accelerate biomarker discovery, development, and application., This work was partially funded by IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 116030 TransQST and GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA: 871075 Elixir-CONVERGE and GA:964537 RISKHUNT3R, which is part of the ASPIS cluster]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519], and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII [PT13/0001/0023, of the PE I + D + i 2013-2016]). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. This work reflects only the author’s view and that the IMI2-JU is not responsible for any use that may be made of the information it contains. The European Commission is not responsible for any use that may be made of the information it contains.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Network, transcriptomic and genomic features differentiate genes relevant for drug response

  • Piñero González, Janet, 1977-
  • Gonzalez-Perez, Abel
  • Guney, Emre
  • Aguirre Plans, Joaquim, 1993-
  • Sanz, Ferran
  • Oliva Miguel, Baldomero
  • Furlong, Laura I., 1971-
Understanding the mechanisms underlying drug therapeutic action and toxicity is crucial for the prevention and management of drug adverse reactions, and paves the way for a more efficient and rational drug design. The characterization of drug targets, drug metabolism proteins, and proteins associated to side effects according to their expression patterns, their tolerance to genomic variation and their role in cellular networks, is a necessary step in this direction. In this contribution, we hypothesize that different classes of proteins involved in the therapeutic effect of drugs and in their adverse effects have distinctive transcriptomics, genomics and network features. We explored the properties of these proteins within global and organ-specific interactomes, using multi-scale network features, evaluated their gene expression profiles in different organs and tissues, and assessed their tolerance to loss-of-function variants leveraging data from 60K subjects. We found that drug targets that mediate side effects are more central in cellular networks, more intolerant to loss-of-function variation, and show a wider breadth of tissue expression than targets not mediating side effects. In contrast, drug metabolizing enzymes and transporters are less central in the interactome, more tolerant to deleterious variants, and are more constrained in their tissue expression pattern. Our findings highlight distinctive features of proteins related to drug action, which could be applied to prioritize drugs with fewer probabilities of causing side effects., We received support from ISCIII-FEDER (PI13/00082, CP10/00524, and CPII16/00026), IMI-JU under grant agreements no. 116030 (TransQST) and no. 777365 (eTRANSAFE) resources of which are composed of financial contribution from the EU-FP7 (FP7/2007-2013) and EFPIA companies in kind contribution, and the EU H2020 Program 2014–2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and was supported by grant PT13/0001/0023, of the PE I+D+i 2013-2016, funded by ISCIII and FEDER. The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the MINECO (ref: MDM-2014-0370). AG-P was supported by a Ramón y Cajal contract (RYC-2013-14554). BO and JA-P were supported by MINECO grant BIO2014-57518-R.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

GUILDify v2.0: a tool to identify molecular networks underlying human diseases, their comorbidities and their druggable targets

  • Aguirre Plans, Joaquim, 1993-
  • Piñero González, Janet, 1977-
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
  • Fernández Fuentes, Narcís
  • Oliva Miguel, Baldomero
  • Guney, Emre
The genetic basis of complex diseases involves alterations on multiple genes. Unraveling the interplay between these genetic factors is key to the discovery of new biomarkers and treatments. In 2014, we introduced GUILDify, a web server that searches for genes associated to diseases, finds novel disease genes applying various network-based prioritization algorithms and proposes candidate drugs. Here, we present GUILDify v2.0, a major update and improvement of the original method, where we have included protein interaction data for seven species and 22 human tissues and incorporated the disease-gene associations from DisGeNET. To infer potential disease relationships associated with multi-morbidities, we introduced a novel feature for estimating the genetic and functional overlap of two diseases using the top-ranking genes and the associated enrichment of biological functions and pathways (as defined by GO and Reactome). The analysis of this overlap helps to identify the mechanistic role of genes and protein-protein interactions in comorbidities. Finally, we provided an R package, guildifyR, to facilitate programmatic access to GUILDify v2.0 (http://sbi.upf.edu/guildify2)., The authors received support from the following:ISCIII–FEDER (PI13/00082, CP10/00524, CPII16/00026); IMI-JU under grants agreements no. 116030(TransQST) and no. 777365 (eTRANSAFE), re-sources of which are composed of financial contribu-tion from the EU-FP7 (FP7/2007- 2013) and EFPIAcompanies in kind contribution; the EU H2020Programme 2014–2020 under grant agreementsno. 634143 (MedBioinformatics) and no. 676559(Elixir-Excelerate); the Spanish Ministry of Economy(MINECO) (BIO2017-85329-R, RYC-2015-17519);and“Unidad de Excelencia María de Maeztu,”fundedby the Spanish Ministry of Economy (ref.: MDM-2014-0370). The Research Programme on BiomedicalInformatics is a member of the Spanish NationalBioinformatics Institute, PRB2-ISCIII, and is supportedby Grant PT13/0001/0023 of the PE I+D+i 2013-2016funded by ISCIII and FEDER
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The eTRANSAFE project on translational safety assessment through integrative knowledge management: achievements and perspectives

  • Pognan, François
  • Centeno, Emilio
  • Furlong, Laura I., 1971-
  • Guney, Emre
  • Mayer, Miguel Ángel, 1960-
  • Pastor Maeso, Manuel
  • Piñero González, Janet, 1977-
  • Ramírez Anguita, Juan Manuel
  • Ronzano, Francesco
  • Saüch Pitarch, Josep
  • Sanz, Ferran
eTRANSAFE is a research project funded within the Innovative Medicines Initiative (IMI), which aims at developing integrated databases and computational tools (the eTRANSAFE ToxHub) that support the translational safety assessment of new drugs by using legacy data provided by the pharmaceutical companies that participate in the project. The project objectives include the development of databases containing preclinical and clinical data, computational systems for translational analysis including tools for data query, analysis and visualization, as well as computational models to explain and predict drug safety events., This research received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreements eTRANSAFE (777365). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA companies in kind contribution.